SHANGHAI, April 26, 2024 /PRNewswire/ -- World Malaria Day is marked each year on April 25. World Health Organization (WHO) gave as the theme for World Malaria Day 2024 Accelerating the fight against malaria for a more equitable world. WHO stated that malaria not only continues to directly endanger health and cost lives, but it also perpetuates a vicious cycle of inequity. People living in the most vulnerable situations including pregnant women and children under 5 years of age continue to be disproportionately impacted.

Artemisinin medicines developed with China's scientific research efforts have become a ticket for China's innovative medicines to go global. According to the WHO World Malaria Report 2023, globally in 2022, there were an estimated 249 million malaria cases and 608,000 malaria deaths. Sub-Saharan Africa accounted for more than 95% of the global malaria cases and deaths. Globally, an estimated 11.7 million malaria deaths were averted in the period 2000-2022. Among them, the average malaria mortality rate (number of deaths per 100,000 population at risk) in Africa decreased from 0.14% per 100,000 population to 0.055%, from 142.6 per 100,000 population in 2020 to 55.5 in 2022. The widespread use of artemisinin medicines is one of the key success factors. Several global multi-center phase III clinical studies and real-world data have shown that artesunate injection is effective in reducing malaria mortality rate.

Self-developed Artemisinin medicines covering from prevention to severe disease treatment

As a leading global R&D and production enterprise of anti-malaria drugs, anti-malaria drugs produced under the R&D and innovation of Fosun Pharma cover malaria prevention, general malaria treatment and severe malaria treatment. A total of 33 products in the anti-malaria series were approved by WHO pre-qualification (WHO PQ), which have made significant contribution to malaria prevention and treatment in countries and regions such as Africa.

In 2010, Artesun®, an artesunate for injection independently developed and manufactured by Fosun Pharma, was approved by WHO PQ. Since 2011, it has been recommended by WHO as a first-line drug for the treatment of severe malaria in children and adults. At the same time, Fosun Pharma is also a supplier of anti-malaria drugs of the Global Fund, UNICEF, WHO and African governments. By the end of 2023, Fosun Pharma has supplied over 340 million doses of artesunate for injection across the world, treating more than 68 million severe malaria patients worldwide.

Meanwhile, Fosun Pharma went deep into the remote areas of African villages and meet the needs of clinicians through continuous innovation. Through process optimization, it has independently developed and launched the second generation of artesunate injection (trade name: Argesun®), which is the first one-step preparation passing the WHO PQ in the world. The preparation time of the drug was reduced from 3 minutes to 1 minute, which can save the time for treating patients with severe malaria. Meanwhile, the concentration of Argesun® was standardized for intravenous and intramuscular injections, which makes it more convenient and safer for clinical purposes.

Artemisinin-based combination therapies (ACTs) are recognized by WHO as the best available treatment. However, in recent years, drug resistance to these therapies has also begun to emerge in Plasmodium falciparum, which is becoming a major threat to malaria control. The global multicenter Phase III clinical trial project led by Fosun Pharma for a triple artemisinin combination drug (Artemether-Lumefantrine-Amodiaquine fixed-dose formulation) against malaria in Africa and Southeast Asia has also received attention from all parties, and the Japan-based Global Health Innovative Technology Fund (GHIT Fund) announced in December 2023 that it will invest approximately US$3.3 million (approximately 500 million yen^[1]), to accelerate the development and commercialization of this new drug. This drug candidate should have a significant public health benefit as it is expected to play an important role in the fight against artemisinin partial resistance (ART-R) which is now observed widely in the Greater Mekong Subregion (GMS) of Southeast Asia^[2] and to some extent in several African countries, including Rwanda and Uganda.

Further improving the accessibility of second generation of Artesunate for injection to benefit remote areas of Africa

From April 21 to 27, the 8th Multilateral Initiative on Malaria (MIM) Pan-African Malaria Conference was held in Kigali-Rwanda. As one of the main sponsors of the conference, Fosun Pharma showcased its full range of antimalarial products and successfully hosted the academic symposium "Improving antimalarial treatment for severe P. falciparum malaria" on April 23. The symposium introduced the recent trends in the global and particularly African burden of severe malaria and the latest treatment and clinical management strategies to over 300 malaria researchers, clinicians, malaria control officials, and NGO representatives from Africa and around the world.

The session was co-chaired by Professor Olugbenga A Mokuolu from Nigeria (Co-Chair of RBM Case Management Working Group; Strategic Adviser on Malaria Elimination to the Honorable Minister of Health Nigeria) and Professor Marielle Bouyou Akotet from the Université des Sciences de la Santé Gabon.

Professor Arjen Dondorp and Professor Joel Tarning from the University of Oxford, and Dr. Samwel Gesase from the National Institute for Medical Research in Tanzania, respectively, presented the important contributions of injectable artesunate in the treatment of severe malaria patients from the epidemiological, clinical pharmacological, and pharmacoeconomic perspectives. They also highlighted the clinical advantages of Fosun Pharma's second-generation of artesunate injection with one-step preparation in the management of severe malaria. The 1.5 hours scientific session was ended by an introduction of the post-discharge malaria chemoprevention, PDMC by Professor Kamija Phiri from Kamuzu University of Health Sciences Malawi.

The attendees highly appreciated the academic professionalism of Fosun Pharma's symposium on severe malaria and recognized Fosun Pharma's commitment to affordable innovation in bringing a new generation of artesunate injection with one-step preparation to Africa. The experts agreed that "artesunate injection is currently the most effective drug for the treatment of severe malaria. The new generation of artesunate injection with one-step preparation will further enhance the convenience of clinical use and reduce the clinical cost of severe malaria treatment, benefiting critically ill children with malaria in remote areas of Africa where medical conditions are poor."

From treatment to prevention, effectively reducing the incidence of severe malaria in children

According to the WHO, children under 5 years old are still the most vulnerable population to malaria infection. in 2022, an estimated 4 out of 5 malaria-related deaths in the African Region were among children under 5 years of age. Inequities in access to education and financial resources further exacerbates risk: children under 5 years of age from the poorest households in sub-Saharan Africa are 5 times more likely to be infected with malaria than those from the wealthiest households.

To improve this situation, Fosun Pharma, in collaboration with the National Malaria Control Program in Africa, continued to carry out the "Promoting Malaria Prevention Knowledge among Children Program" in 14 malaria-prone countries in Africa, targeting at the community level, in order to raise the awareness of malaria prevention among the local population in Africa, and to help reduce the incidence rate of malaria and interrupt the transmission of malaria in the community. In August 2018, Fosun Pharma's SPAQ-CO^® Disp (co-packed sulfadoxine-pyrimethamine dispersible tablets and amodiaquine dispersible tablets), for the prevention of malaria in children, was approved by WHO PQ . By the end of 2023, more than 258 million children in Africa had benefited from the "Seasonal Malaria Chemoprevention Program", for which SPAQ-CO^® Disp is used as the core drug, effectively reducing the incidence of malaria in children under five years old in Africa.

Promoting the localization of pharmaceutical production and helping to enhance the healthcare capacity of developing countries

Based in China and with a global presence, Fosun Pharma has always been committed to providing high-quality medical solutions to patients worldwide. It actively expands its business in emerging markets, including Africa, India and Southeast Asia, to improve the accessibility of medicines in developing countries. By the end of 2023, Fosun Pharma had established five regional distribution centers in emerging markets. The overseas commercialization team consists of approximately 1,000 people, dedicated to enhancing the accessibility of pharmaceutical products.

To achieve localized pharmaceutical manufacturing and supply in Africa and to enhance the accessibility and affordability of pharmaceutical and healthcare products in the African region, Fosun Pharma's Cote d'Ivoire park project was initiated in November 2022. The project is planned to be carried out in three phases, with the first phase expected to be completed in 2024. Upon completion of the project, the production capacity of the park will be expanded to 5 billion tablets per year and include a warehouse with a storage capacity of 10,000 pallets, which is expected to bring nearly 1,000 job opportunities to the Greater Bassam area and effectively promote the development of the pharmaceutical industry in Cote d'Ivoire.

About Fosun Pharma

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* ("Fosun Pharma"; stock code: 600196. SH, 02196. HK) is a global innovation-driven pharmaceutical and healthcare industry group. Fosun Pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.

Fosun Pharma is patient-centered and clinical needs-oriented. The company continuously enriches its innovative product pipeline through independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma improves the research and clinical development capabilities of FIC (First-in-class) and BIC (Best-in-class) new drugs as well as accelerates the R&D and launch of innovative technologies and products. Fosun Pharma's innovative products mainly covered core therapeutic areas such as tumors (solid tumors and hematologic tumors), immunology, central nervous system, and chronic diseases (liver disease/metabolism/kidney disease).

Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma will uphold the development model of "Innovation Transformation, Integrated Operation and Steady Growth", with the mission of creating shareholder values through strengthening its independent R&D and external cooperation and enriching its product pipelines, as well as promoting the global networks and enhancing operational efficiency. Fosun Pharma will actively promote the digital and physical business layout in the pharmaceutical and healthcare industry and is committed to becoming a first-class enterprise in the global pharmaceutical and healthcare markets.

For more information, please visit our official website: www.fosunpharma.com 

PARIS, April 25, 2024 /PRNewswire/ -- Zoomlion Heavy Industry Science & Technology Co., Ltd. ("Zoomlion", 01157.HK) proudly showcased its latest advancements at INTERMAT, held at the Nord Villepinte Exhibition Center in Paris from April 24-27, 2024. Themed "Greener Development, Brighter Future", the display featured approximately 30 cutting-edge products across seven major categories, underscoring Zoomlion's commitment to sustainable and intelligent product solutions.

The exhibit included a vibrant array of new-generation machinery such as engineering and construction cranes, concrete machinery, earth-moving equipment, aerial work platforms, and more, all noted for their high-end, intelligent, and eco-friendly features.

A highlight was the R135-8RA tower crane, which incorporates major innovations such as remote safety inspections and equipment adjustments, demonstrating Zoomlion's leadership in smart machinery. Visitors at the Paris venue could remotely operate this crane, located over 8,000 kilometers away in Changde, Hunan, through 5G technology, experiencing the intelligent capabilities of Zoomlion's products firsthand.

Aligned with the theme "Greener Development, Brighter Future," the showcase prominently featured new energy products including hybrid concrete mixers, electric aerial work platforms, and lithium battery industrial vehicles. It also highlighted energy-efficient technologies in pumps, cranes, and earth-moving equipment, reinforcing the company's dedication to low-carbon development.

The company's strategic localization efforts are evident, with products like the 43X-5RZ concrete pump truck, which meets stringent European road regulations and CE certification standards. These adaptations ensure Zoomlion's offerings are well-suited to European market demands, emphasizing performance, technological innovation, and user-friendly design.

Zoomlion is enhancing its European market penetration by strengthening synergies with subsidiaries such as CIFA in Italy and m-tec in Germany. On the first day of the exhibition, Zoomlion announced significant contracts with clients from Germany and Poland, with the contract value for concrete products alone nearing 100 million Yuan (US$13.8 million), marking a robust start.

Over recent years, Zoomlion has capitalized on internet-based strategies to develop a unique end-to-end, digital, and localized global business system. This approach has propelled strong growth in international markets, with Zoomlion's products and services now available in over 140 countries and regions, supported by more than 3,000 localized employees worldwide.

"Zoomlion commits to fostering sustainable and high-quality development in the construction machinery industry. As INTERMAT continues, we invite attendees to experience our innovative solutions firsthand," said Yuan Ye, Zoomlion's Assistant President. "We look forward to strengthening partnerships and showcasing our technological advancements that drive the global industry forward," Yuan added.

HONG KONG, April 25, 2024 /PRNewswire/ -- CNOOC Limited (the "Company", SEHK: 00883 (HKD Counter) and 80883 (RMB Counter), SSE: 600938) today announced its operating results for the first quarter of 2024.

In the first quarter, the Company pressed ahead with oil and gas exploration and development, advanced the enhancement of quality and efficiency, and consolidated its advantage of cost competitiveness. Net production of oil and gas and net profit attributable to equity shareholders achieved strong growth, both hitting new highs for the same period.

During the quarter, CNOOC Limited recorded a total net production of 180.1 million barrels of oil equivalent ("BOE"), representing an increase of 9.9% year-on-year ("YoY"). The net production from China grew by 6.9% YoY to 123.2 million BOE, which was mainly attributable to the production from the newly commissioned projects. Overseas net production rose by 16.9% YoY to 56.9 million BOE, which was mainly driven by increased production from Guyana and Canada.

The Company made 2 new discoveries and successfully appraised 4 oil and gas structures. In particular, Bozhong 8-3 South in offshore China was successfully appraised, opening up a new exploration chapter in ultra-deep plays offshore China. Overseas, a new discovery, Bluefin, was made at the Stabroek block in Guyana, further expanding the resource base in the southeastern portion of the block. During the period, Suizhong 36-1/Luda 5-2 Oilfield Secondary Adjustment and Development Project commenced production. Other major new projects, such as the Shenhai-1 Phase II Natural Gas Development Project, progressed smoothly.

In the first quarter of 2024, in spite of lower international oil prices, CNOOC Limited generated a net profit attributable to equity shareholders of RMB39.7 billion, representing a YoY growth of 23.7%, showing strong value creation capability. The all-in cost was US$27.59 per BOE, a decrease of 2.2% YoY. The Company's capital expenditures amounted to approximately RMB29 billion, increased by 17.3% YoY, which was mainly because of the increased workloads at projects under construction and adjustment wells.

Mr. Zhou Xinhuai, CEO and President of the Company, said, "In the first quarter, CNOOC Limited continued to make breakthroughs in exploration, obtained strong growth in oil and gas production and achieved its best-ever net profit for the same period in history. We will stay focused on our annual production and operation goals, continue to pursue increase of reserves and production, strengthen lean management, and consolidate the high-quality development of the Company."

— End —

Notes to Editors:

More information about the Company is available at http://www.cnoocltd.com.

*** *** *** ***

This press release includes forward looking information, including statements regarding the likely future developments in the business of the Company and its subsidiaries, such as expected future events, business prospects or financial results. The words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify such forward-looking statements. These statements are based on assumptions and analyses made by the Company as of this date in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company currently believes are appropriate under the circumstances. However, whether actual results and developments will meet the current expectations and predictions of the Company is uncertain. Actual results, performance and financial condition may differ materially from the Company's expectations, including but not limited to those associated with fluctuations in crude oil and natural gas prices, macro-political and economic factors, changes in the tax and fiscal regimes of the host countries in which we operate, the highly competitive nature of the oil and natural gas industry, environmental responsibility and compliance requirements, the Company's price forecast, the exploration and development activities, mergers, acquisitions and divestments activities, HSSE and insurance policies and changes in anti-corruption, anti-fraud, anti-money laundering and corporate governance laws.

Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements. The Company cannot assure that the results or developments anticipated will be realised or, even if substantially realised, that they will have the expected effect on the Company, its business or operations.

*** *** *** ***

For further enquiries, please contact:

Ms. Cui Liu
Media & Public Relations
CNOOC Limited
Tel: +86-10-8452-6641
Fax: +86-10-8452-1441
E-mail: mr@cnooc.com.cn 

Mr. Bunny Lee
Porda Havas International Finance Communications Group
Tel: +852 3150 6707
Fax: +852 3150 6728
E-mail: cnooc.hk@pordahavas.com

香港2024年4月25日 /美通社/ -- 中國海洋石油有限公司（「公司」或「中國海油」，香港聯交所股票代碼：00883（港幣櫃台）及80883（人民幣櫃台），上海證券交易所股票代碼：600938）今天公佈了2024年一季度經營業績。

第一季度，公司持續加大油氣勘探開發力度，扎實推進提質增效升級行動，成本競爭優勢得到鞏固。油氣淨產量和歸母淨利潤實現強勁增長，兩項數據均創歷史同期新高。

期內，中國海油實現淨產量180.1百萬桶油當量，同比增長9.9%。其中，中國淨產量123.2百萬桶油當量，同比上升6.9%，主要來源於新項目投產帶來的產量貢獻；海外淨產量56.9百萬桶油當量，同比上升16.9%，主要原因是圭亞那和加拿大產量增加。

公司共獲得2個新發現，並成功評價4個含油氣構造。其中，中國海域成功評價渤中8-3南，開闢了海上超深層油氣勘探新領域。在海外，圭亞那Stabroek區塊獲得新發現Bluefin，進一步擴大了該區塊東南部儲量規模。期內，綏中36-1/旅大5-2油田二次調整開發項目成功投產，深海一號二期等重點新項目順利推進。

2024年第一季度，在國際油價同比下降的環境下，中國海油實現歸屬于母公司股東的淨利潤人民幣397億元，同比上漲23.7%，價值創造能力持續提升。桶油主要成本為27.59美元，同比下降2.2%。此外，公司資本支出約人民幣290億元，同比上升17.3%，主要原因是在建項目及調整井工作量同比有所增加。

中國海油首席執行官及總裁周心懷先生表示：「一季度，中國海油勘探繼續突破，油氣產量保持強勁增長，淨利潤實現歷史同期最好水平。我們將錨定全年生產經營目標不動搖，繼續扎實推進增儲上產，深化精益化管理，全力推動中國海油高質量發展再上新台階。」

— 完 —

編者注：

如需瞭解中國海洋石油有限公司更多信息，請登錄公司網站http://www.cnoocltd.com

*** *** *** ***

本新聞稿包含公司的前瞻性資料，包括關於本公司和其附屬公司業務相當可能有的未來發展的聲明，例如預期未來事件、業務展望或財務結果。「預期」、「預計」、「繼續」、「估計」、「目標」、「持續」、「可能」、「將會」、「預測」、「應當」、「相信」、「計劃」、「旨在」等詞彙以及相似表達意在判定此類前瞻性聲明。這些聲明以本公司在此日期根據其經驗以及對歷史發展趨勢，目前情況以及預期未來發展的理解，以及本公司目前相信的其它合理因素所做出的假設和分析為基礎。然而，實際結果和發展是否能夠達到本公司的目前預期和預測存在不確定性。實際業績、表現和財務狀況可能與本公司的預期產生重大差異，這些因素包括但不限於宏觀政治及經濟因素、原油和天然氣價格波動有關的因素、石油和天然氣行業高競爭性的本質、氣候變化及環保政策因素、公司價格前瞻性判斷、併購剝離活動、HSSE及保險安排、以及反腐敗反舞弊反洗錢和公司治理相關法規變化。

因此，本新聞稿中所做的所有前瞻性聲明均受這些謹慎性聲明的限制。本公司不能保證預期的業績或發展將會實現，或者即便在很大程度上得以實現，本公司也不能保證其將會對本公司、其業務或經營產生預期的效果。

*** *** *** ***

如有進一步查詢，請聯絡：

劉  翠
媒體/公共關係
中國海洋石油有限公司
電話：+86-10-8452-6641
傳真：+86-10-8452-1441
電郵：mr@cnooc.com.cn 

李耀榮
博達浩華國際財經傳訊集團
電話: +852 3150 6707
傳真: +852 3150 6728
電郵：cnooc.hk@pordahavas.com

SAN FRANCISCO and SUZHOU, China, April 25, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that about 20 accepted abstracts of clinical data from multiple trials in relation to multiple novel mono-/bi-specific antibodies and antibody-drug-conjugates (ADCs) as well as innovative drugs including TYVYT® (sintilimab injection), olverembatinib, taletrectinib (ROS1 TKI) from its oncology pipeline will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 from May 31 to June 4, 2024, in Chicago, IL, U.S..

Dr. Hui Zhou, Senior Vice President of Innovent, stated: "We are very pleased to present a robust set of clinical data for our next-generation innovative bispecific antibodies and ADC molecules for the first time at the 2024 ASCO Annual Meeting. We observed the preliminary efficacy and safety signals for those innovative candidates, underscoring their potential for further development and clinical value. As one of the few biopharmaceutical companies with both the technology platforms and robust pipeline in "IO+ADC" areas, Innovent will continue to make breakthroughs in the field of cancer treatment, and is committed to providing doctors and patients with more innovative, effective and safe treatment options."

Details on the abstracts are listed below:

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to provide high-quality biologics that are affordable to all. The company discovers, develops, manufactures and commercializes innovative medicines that treat some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has 10 products in the market, 3 new drug applications under the NMPA review, 5 assets in Phase III or pivotal clinical trials and 18 more molecules in early clinical stage. Innovent partners with over 30 global healthcare leaders, including Eli Lilly, Roche, Sanofi, Adimab, Incyte and MD Anderson Cancer Center.

Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s).

Forward-looking statement

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions.

The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.

美國舊金山和中國蘇州2024年4月25日 /美通社/ -- 信達生物制藥集團（香港聯交所股票代碼：01801），一家致力於研發、生產和銷售腫瘤、自身免疫、代謝及心血管、眼科等重大疾病領域創新藥物的生物制藥公司，今日宣布，將在 2024 年美國臨床腫瘤學會（ASCO）年會上公布約20項最新臨床研究數據，包括公司旗下一系列單抗、雙抗及抗體偶聯藥物（ADC）在研管線，及達伯舒^®（信迪利單抗注射液）、耐立克^®（奧雷巴替尼）、他雷替尼（ROS1抑制劑）等創新腫瘤藥物。本屆 ASCO 年會將於當地時間2024年5月31日-6月4日在美國芝加哥舉辦。

信達生物制藥集團高級副總裁周輝博士表示：「很高興在本次ASCO大會上首次公布了信達生物多個下一代創新腫瘤雙抗及ADC分子的臨床數據，早期探索取得的成果令我們欣喜，也使我們對於進一步開發充滿信心。作為少數擁有「IO+ADC」技術平台和充沛管線儲備的生物制藥企業，信達生物將在癌症治療領域持續取得突破，致力於為醫生和患者提供更創新、有效和安全的治療手段及方案。」

重要臨床研究結果摘要信息如下：

關於信達生物

「始於信，達於行」，開發出老百姓用得起的高質量生物藥，是信達生物的使命和目標。信達生物成立於2011年，致力於研發、生產和銷售腫瘤、自身免疫、代謝、眼科等重大疾病領域的創新藥物，讓我們的工作惠及更多的生命。公司已有10個產品獲得批准上市，它們分別是信迪利單抗注射液（達伯舒^®），貝伐珠單抗注射液（達攸同^®），阿達木單抗注射液（蘇立信^®），利妥昔單抗注射液（達伯華^®），佩米替尼片（達伯坦^®），奧雷巴替尼片（耐立克^®）， 雷莫西尤單抗注射液（希冉擇^®）²，塞普替尼膠囊（睿妥^®）²，伊基奧侖賽注射液（福可蘇^®）和托萊西單抗注射液（信必樂^®）。目前，同時還有3個品種在NMPA審評中，5個新藥分子進入III期或關鍵性臨床研究，另外還有18個新藥品種已進入臨床研究。

公司已與禮來、羅氏、賽諾菲、Adimab、Incyte和MD Anderson 癌症中心等國際合作方達成30多項戰略合作。信達生物在不斷自研創新藥物、謀求自身發展的同時，秉承經濟建設以人民為中心的發展思想。多年來，始終心懷科學善念，堅守「以患者為中心」，心系患者並關注患者家庭，積極履行社會責任。公司陸續發起、參與了多項藥品公益援助項目，讓越來越多的患者能夠得益於生命科學的進步，買得到、用得起高質量的生物藥。至2023年底，信達生物患者援助項目已惠及17余萬普通患者，藥物捐贈總價值34億元人民幣。信達生物希望和大家一起努力，提高中國生物制藥產業的發展水平，以滿足百姓用藥可及性和人民對生命健康美好願望的追求。

詳情請訪問公司網站：www.innoventbio.com或公司領英賬號www.linkedin.com/company/innovent-biologics/。

前瞻性聲明

本新聞稿所發布的信息中可能會包含某些前瞻性表述。這些表述本質上具有相當風險和不確定性。在使用「預期」、「相信」、「預測」、「期望」、「打算」及其他類似詞語進行表述時，凡與本公司有關的，目的均是要指明其屬前瞻性表述。本公司並無義務不斷地更新這些預測性陳述。

這些前瞻性表述乃基於本公司管理層在做出表述時對未來事務的現有看法、假設、期望、估計、預測和理解。這些表述並非對未來發展的保證，會受到風險、不確性及其他因素的影響，有些乃超出本公司的控制范圍，難以預計。因此，受我們的業務、競爭環境、政治、經濟、法律和社會情況的未來變化及發展的影響，實際結果可能會與前瞻性表述所含資料有較大差別。

PISCATAWAY, N.J., April 24, 2024 /PRNewswire/ -- Recently, GenScript Biotech Corporation (HK.1548), a world leader in technologies and services for life science R&D and manufacture, released its 2023 Environmental, Social, and Governance (ESG) report. This report showcases the company's dedicated efforts in ESG governance, corporate social responsibility fulfillment, and environmental conservation practices. It underscores GenScript's unwavering commitment to advancing green initiatives and seamlessly integrating sustainable development strategies, reaffirming its strong belief in sustainability.

GenScript's ESG plan embodies its comprehensive and in-depth enhancement strategy, focusing on optimizing production processes, deepening customer R&D support, and advancing lean operations to enhance overall ESG performance. GenScript believes that ESG practices complement business growth, driving sustainable business expansion and positively impacting human society's sustainability. Through close collaboration with customers and continuous improvement of ESG standards, GenScript actively contributes to society.

In strengthening corporate ESG governance, GenScript demonstrates firm determination and systematic planning. The company establishes a risk management and ESG committee at the board level and deploys a cross-departmental ESG management team to continuously monitor and improve ESG practices. Additionally, GenScript maintains high ethical standards, providing anti-corruption training for all employees, strengthening institutional construction, and implementing rigorous annual audit plans to ensure strict compliance with business ethics and legal regulations, thus enhancing risk management and ESG governance.

In terms of fulfilling social responsibilities, GenScript adheres to sustainability as its core value, striving to provide safer and more reliable products and services to global customers. The company actively promotes the development of green and resilient supply chains with its supplier partners, integrating ESG indicators into supplier evaluations and cooperation mechanisms to drive transparency and performance improvement throughout the supply chain's lifecycle.

Moreover, GenScript prioritizes employee growth and well-being, fostering an inclusive and diverse corporate culture. Through comprehensive training systems, diversified career development channels, and efficient communication mechanisms, the company promotes symbiotic growth between employees and the organization. Furthermore, GenScript engages in philanthropic activities, such as organizing "Rare Disease Awareness Weeks", donating to earthquake-stricken areas, and hosting nationwide universities relay charity events, enriching the company's social responsibility endeavors with tangible actions.

The ESG report further illustrates GenScript's environmental practices, emphasizing resource management, waste management, and proactive green actions to combat climate change. By establishing a scientific and efficient environmental management system, optimizing resource utilization, and exploring clean energy transitions, GenScript reduces its environmental footprint. The company implements energy-saving measures such as continuous improvement of production and equipment processes and waste heat recovery, linking environmental performance to management evaluations from top to bottom.

This year, GenScript has further integrated renewable energy into its energy portfolio, purchasing green power and investing in photovoltaic power generation. In April 2024, GenScript joined the Science-Based Targets initiative (SBTi), committing to scientific carbon goals and planning comprehensive carbon inventories and product carbon footprint identification to set scientific carbon targets. These efforts not only help reduce the company's environmental impact but also assist its customers in achieving carbon reduction goals, collectively fostering a favorable pattern of collaborative emission reduction throughout the industry chain.

Sherry Shao, GenScript's rotating CEO, said, "2023 was a critical year for GenScript's ESG practices. We took proactive actions to build a systematic framework for sustainable development and deeply integrated ESG concepts into the company's daily operations and long-term planning through the collaborative efforts of management, employees, and numerous stakeholders. Here, we sincerely thank all parties for their continuous support of GenScript's business development. In the future, we are willing to work hand in hand with all parties to tirelessly strive for the mission of 'Make People and Nature Healthier Through Biotechnology'."

In the pursuit of sustainable development and continuous enhancement of ESG standards, GenScript demonstrates a firm long-term commitment. In 2023, the company officially joined the United Nations Global Compact (UNGC) and integrated principles such as human rights, labor rights, environmental protection, and anti-corruption into its strategic planning, aiming to leverage the power of this international platform to deepen innovation and improvement in the ESG field. With significant improvements in environmental and sustainable procurement performance, GenScript was awarded the Bronze Medal by the international renowned provider of business sustainability ratings EcoVadis in March this year, ranking among the top 35% of over 130,000 assessed companies.

Moving forward, GenScript will continue to elevate its ESG standards, seize opportunities, and collaborate with stakeholders in a more open and transparent manner to collectively advance sustainable development goals. The "GenScript Biotech 2023 ESG Report" is available at company's official website:

https://www.genscript.com/gsfiles/esg/2023-ESG-Report.pdf

About GenScript

GenScript Biotech Corporation (HK.1548) is a world leader in technologies and services for life science R&D and manufacture. Built upon its solid DNA synthesis technology, the company comprises four major business units: a life-science services and products business unit, a biologics contract development and manufacturing organization (CDMO) business unit, an industrial synthetic products business unit, and an integrated global cell therapy company. GenScript accelerates scientific discovery and therapeutic breakthrough with its customers. Since its founding in New Jersey, USA in 2002, GenScript has expanded its operations to serve more than 200,000 customers across 100 countries with a dedicated team of 6,900 employees. As of December 31, 2023, 87,700 peer-reviewed journal articles worldwide had cited GenScript 's services and products. Guided by its mission to make people and nature healthier through biotechnology, GenScript strives to become the most trustworthy biotech company in the world.

For more information, please visit GenScript Biotech's official website

https://www.genscript.com

BEIJING, April 24, 2024 /PRNewswire/ -- New Oriental Education & Technology Group Inc. (the "Company" or "New Oriental") (NYSE: EDU/ 9901.SEHK), a provider of private educational services in China, today announced its unaudited financial results for the third fiscal quarter ended February 29, 2024, which is the third quarter of New Oriental's fiscal year 2024.

Financial Highlights for the Third Fiscal Quarter Ended February 29, 2024

• Total net revenues increased by 60.1% year over year to US$1,207.3 million for the third fiscal quarter of 2024.
• Operating income increased by 70.6% year over year to US$113.4 million for the third fiscal quarter of 2024.
• Net income attributable to New Oriental increased by 6.8% year over year to US$87.2 million for the third fiscal quarter of 2024.

Key Financial Results

(1)  Each ADS represents ten common shares. The Hong Kong-listed shares are fully fungible with the ADSs listed on NYSE.

(2)  GAAP represents Generally Accepted Accounting Principles in the United States of America.

(3)  New Oriental provides net income attributable to New Oriental, operating income and net income per ADS attributable to New Oriental on a non-GAAP basis that excludes share-based compensation expenses and gain from fair value change of investments to provide supplemental information regarding its operating performance. For more information on these non-GAAP financial measures, please see the section captioned "About Non-GAAP Financial Measures" and the tables captioned "Reconciliations of Non-GAAP Measures to the Most Comparable GAAP Measures" set forth at the end of this release.

(4)  The Non-GAAP net income per ADS attributable to New Oriental is computed using Non-GAAP net income attributable to New Oriental and the same number of shares and ADSs used in GAAP basic and diluted EPS calculation.

Operating Highlights for the Third Fiscal Quarter Ended February 29, 2024

• The total number of schools and learning centers was 911 as of February 29, 2024, an increase of 68 and 199 compared to 843 as of November 30, 2023 and 712 as of February 28, 2023, respectively. The total number of schools was 81 as of February 29, 2024.

Michael Yu, New Oriental's Executive Chairman, commented, "We are pleased to see a continued acceleration of our growth momentum that exceeded our expectation in the third quarter of fiscal year 2024, characterized by a remarkable top line growth of 60.1%. Our overseas test preparation and overseas study consulting businesses maintained a strong upward trajectory, exhibiting approximately 52.6% and 25.7% growth year over year, respectively. In addition, the domestic test preparation business targeting adults and university students recorded a growth of approximately 53.2% year over year. Moreover, it is also encouraging that our new educational business initiatives have all achieved promising results in this fiscal quarter, with 72.7% revenue growth year over year. Among these new educational business initiatives, our non-academic tutoring courses were offered in around 60 cities, attracting approximately 355,000 student enrollments in this fiscal quarter. Simultaneously, our intelligent learning system and devices were adopted in around 60 cities, with approximately 188,000 active paid users in this fiscal quarter. In addition to our robust growth momentum, our unwavering commitment to enhancing teaching quality and fostering an enriching learning experience for our students is evidenced by our continuous improvement in customer retention rate. I am confident to say New Oriental is well-positioned in its capacity to capture current and future market opportunities, leveraging its well-established brand and abundant educational resources."

Chenggang Zhou, New Oriental's Chief Executive Officer, added, "During this fiscal quarter, we continued to expand our capacity in some existing cities with greater growth potential and higher facility utilization, thereby increasing profitability at a moderate pace. Our total number of schools and learning centers increased to 911 by the end of this fiscal quarter. To support the strong recovery of our remaining key businesses and the rapid development of new educational initiatives, we continued to allocate resources to our online-merge-offline teaching system and apply new technologies to enhance the quality of our educational and product offerings. Notably, we made substantial investments in East Buy (东方甄选), enhancing the development of its private label products and its presence in multiple channels to attract a larger customer base with its premium products and innovative livestreaming content. While East Buy continued to grow, it also implemented comprehensive measures, including strengthening its supply chain management system to better control food safety and product quality, expanding product categories and increasing SKUs, to reaffirm its commitment to delivering high-quality products with good value for money."

Stephen Zhihui Yang, New Oriental's Executive President and Chief Financial Officer, commented, "Our GAAP operating margin for the quarter was 9.4% and Non-GAAP operating margin for the quarter was 11.7%. Following the promising development in the previous quarters, our educational businesses continued a significant year over year improvement in operating margin in this quarter, driven by strong revenue growth and enhanced utilization of facilities and teaching resources. We recorded a positive operating cash flow of US$109.4 million for this quarter, and by the end of this fiscal quarter, our cash and cash equivalents, term deposits and short-term investments totaled approximately US$4.8 billion. We are confident in achieving healthy growth across all business lines while enhancing operational efficiency and creating sustainable value for our customers and shareholders in the long term."

Share Repurchase

On July 26, 2022, the Company's board of directors authorized a share repurchase program, under which the Company may repurchase up to US$400 million of the Company's ADSs or common shares during the period from July 28, 2022 through May 31, 2023. The Company's board of directors further authorized to extend such share repurchase program by twelve months through May 31, 2024. As of April 23, 2024, the Company repurchased an aggregate of approximately 6.0 million ADSs for approximately US$195.3 million from the open market under the share repurchase program.

Financial Results for the Third Fiscal Quarter Ended February 29, 2024

Net Revenues

For the third fiscal quarter of 2024, New Oriental reported net revenues of US$1,207.3 million, representing a 60.1% increase year over year. The growth was mainly driven by the increase in net revenues from our educational new business initiatives and East Buy private label products and livestreaming e-commerce business.

Operating Costs and Expenses

Operating costs and expenses for the quarter were US$1,093.9 million, representing a 59.1% increase year over year. Non-GAAP operating costs and expenses for the quarter, which exclude share-based compensation expenses, were US$1,066.4 million, representing a 60.1% increase year over year. The increase was primarily due to the cost and expenses related to the substantial growth in East Buy private label products and livestreaming e-commerce business.

• Cost of revenues increased by 74.5% year over year to US$644.8 million.
• Selling and marketing expenses increased by 57.1% year over year to US$161.3 million.
• General and administrative expenses for the quarter increased by 33.6% year over year to US$287.8 million. Non-GAAP general and administrative expenses, which exclude share-based compensation expenses, were US$273.6 million, representing a 40.7% increase year over year.

Total share-based compensation expenses, which were allocated to related operating costs and expenses, increased by 28.3% to US$27.5 million in the third fiscal quarter of 2024.

Operating Income and Operating Margin

Operating income was US$113.4 million, representing a 70.6% increase year over year. Non-GAAP income from operations for the quarter was US$140.9 million, representing a 60.3% increase year over year.

Operating margin for the quarter was 9.4%, compared to 8.8% in the same period of the prior fiscal year. Non-GAAP operating margin, which excludes share-based compensation expenses, for the quarter was 11.7%, compared to 11.7% in the same period of the prior fiscal year.

Net Income and Net Income per ADS

Net income attributable to New Oriental for the quarter was US$87.2 million, representing a 6.8% increase year over year. Basic and diluted net income per ADS attributable to New Oriental were US$0.53 and US$0.52, respectively.

Non-GAAP Net Income and Non-GAAP Net Income per ADS

Non-GAAP net income attributable to New Oriental for the quarter was US$104.7 million, representing a 9.8% increase year over year. Non-GAAP basic and diluted net income per ADS attributable to New Oriental were US$0.63 and US$0.63, respectively.

Cash Flow

Net operating cash inflow for the third fiscal quarter of 2024 was approximately US$109.4 million and capital expenditures for the quarter were US$80.1 million.

Balance Sheet

As of February 29, 2024, New Oriental had cash and cash equivalents of US$2,013.6 million. In addition, the Company had US$1,570.8 million in term deposits and US$1,175.3 million in short-term investment.

New Oriental's deferred revenue, which represents cash collected upfront from customers and related revenue that will be recognized as the services or goods are delivered, at the end of the third quarter of fiscal year 2024 was US$1,521.7 million, an increase of 30.8% as compared to US$1,163.2 million at the end of the third quarter of fiscal year 2023.

Financial Results for the Nine Months Ended February 29, 2024

For the first nine months of fiscal year 2024, New Oriental reported net revenues of $3,176.9 million, representing a 48.6% increase year over year.

Operating income was US$339.9 million, representing a 139.4% increase year over year. Non-GAAP income from operations for the first nine months of fiscal year 2024 was US$436.6 million, representing a 116.9% increase year over year.

Operating margin for the first nine months of fiscal year 2024 was 10.7%, compared to 6.6% for the same period of the prior fiscal year. Non-GAAP operating margin, which excludes share-based compensation expenses for the first nine months of fiscal year 2024, was 13.7%, compared to 9.4% for the same period of the prior fiscal year.

Net income attributable to New Oriental for the first nine months of fiscal year 2024 was US$282.6 million, representing a 90.5% increase year over year. Basic and diluted net income per ADS attributable to New Oriental for the first nine months of fiscal year 2024 amounted to US$1.71 and US$1.69, respectively.

Non-GAAP net income attributable to New Oriental for the first nine months of fiscal year 2024 was US$344.2 million, representing a 74.9% increase year over year. Non-GAAP basic and diluted net income per ADS attributable to New Oriental for the first nine months of fiscal year 2024 amounted to US$2.08 and US$2.05, respectively.

Outlook for the Fourth Quarter of the Fiscal Year 2024

New Oriental expects total net revenues in the fourth quarter of the fiscal year 2024 (March 1, 2024 to May 31, 2024) to be in the range of US$1,101.5 million to US$1,127.3 million, representing year over year increase in the range of 28% to 31%.

The projected increase of revenue in our functional currency Renminbi is expected to be in the range of 34% to 37% for the fourth quarter of the fiscal year 2024.

This forecast reflects New Oriental's current and preliminary view, which is subject to change.

Conference Call Information

New Oriental's management will host an earnings conference call at 8 AM on April 24, 2024, U.S. Eastern Time (8 PM on April 24, 2024, Beijing/Hong Kong Time). 

Please register in advance of the conference, using the link provided below. Upon registering, you will be provided with participant dial-in numbers, and unique personal PIN.

Conference call registration link: https://register.vevent.com/register/BI0b65461f12d9499caeb6af9d65a36784. It will automatically direct you to the registration page of "New Oriental FY2024 Q3 Earnings Conference Call" where you may fill in your details for RSVP.

In the 10 minutes prior to the call start time, you may use the conference access information (including dial in number(s) and personal PIN) provided in the confirmation email received at the point of registering.

Joining the conference call via a live webcast:

Additionally, a live and archived webcast of the conference call will be available at http://investor.neworiental.org.

Listening to the conference call replay:

A replay of the conference call may be accessed via the webcast on-demand by registering at https://edge.media-server.com/mmc/p/bv5iumbf first. The replay will be available until April 24, 2025.

About New Oriental

New Oriental is a provider of private educational services in China offering a wide range of educational programs, services and products to a varied student population throughout China. New Oriental's program, service and product offerings mainly consist of educational services and test preparation courses, private label products and livestreaming e-commerce and other services, overseas study consulting services, and educational materials and distribution. New Oriental is listed on NYSE (NYSE: EDU) and SEHK (9901.SEHK), respectively. New Oriental's ADSs, each of which represents ten common shares, are listed and traded on the NYSE. The Hong Kong-listed shares are fully fungible with the ADSs listed on NYSE.

For more information about New Oriental, please visit http://www.neworiental.org/english/.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the outlook for the fourth quarter of fiscal year 2024, quotations from management in this announcement, as well as New Oriental's strategic and operational plans, contain forward-looking statements. New Oriental may also make written or oral forward-looking statements in its reports filed or furnished to the U.S. Securities and Exchange Commission, in its annual reports to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about New Oriental's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: our ability to effectively and efficiently manage changes of our existing business and new business; our ability to execute our business strategies; uncertainties in relation to the interpretation and implementation of or proposed changes to, the PRC laws, regulations and policies regarding the private education industry; our ability to attract students without a significant increase in course fees; our ability to maintain and enhance our "New Oriental" brand; our ability to maintain consistent teaching quality throughout our school network, or service quality throughout our brand; our ability to achieve the benefits we expect from recent and future acquisitions; the outcome of ongoing, or any future, litigation or arbitration, including those relating to copyright and other intellectual property rights; competition in the private education sector and livestreaming e-commerce business in China; the continuing efforts of our senior management team and other key personnel, health epidemics and other outbreaks in China; and general economic conditions in China. Further information regarding these and other risks is included in our annual report on Form 20-F and other documents filed with the Securities and Exchange Commission. New Oriental does not undertake any obligation to update any forward-looking statement, except as required under applicable law. All information provided in this press release and in the attachments is as of the date of this press release, and New Oriental undertakes no duty to update such information, except as required under applicable law.

About Non-GAAP Financial Measures

To supplement New Oriental's consolidated financial results presented in accordance with GAAP, New Oriental uses the following measures defined as non-GAAP financial measures by the SEC: net income excluding share-based compensation expenses and gain from fair value change of investments, operating income excluding share-based compensation expenses, operating cost and expenses excluding share-based compensation expenses, general and administrative expenses excluding share-based compensation expenses, operating margin excluding share-based compensation expenses, and basic and diluted net income per ADS and per share excluding share-based compensation expenses and gain from fair value change of investments. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. For more information on these non-GAAP financial measures, please see the tables captioned "Reconciliations of non-GAAP measures to the most comparable GAAP measures" set forth at the end of this release.

New Oriental believes that these non-GAAP financial measures provide meaningful supplemental information regarding its performance and liquidity by excluding share-based compensation expenses and gain from fair value change of investments that may not be indicative of its operating performance from a cash perspective. New Oriental believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its performance and when planning and forecasting future periods. These non-GAAP financial measures also facilitate management's internal comparisons to New Oriental's historical performance and liquidity. New Oriental believes these non-GAAP financial measures are useful to investors in allowing for greater transparency with respect to supplemental information used by management in its financial and operational decision making. A limitation of using these non-GAAP measures is that they exclude share-based compensation charge and gain from fair value change of investments that has been and will continue to be for the foreseeable future a significant recurring expense in our business. Management compensates for these limitations by providing specific information regarding the GAAP amounts excluded from each non-GAAP measure. The accompanying tables have more details on the reconciliations between GAAP financial measures that are most directly comparable to non-GAAP financial measures.

Contacts

For investor and media inquiries, please contact:

Ms. Rita Fong                                                    Ms. Sisi Zhao
FTI Consulting                                                   New Oriental Education & Technology Group Inc.
Tel:   +852 3768 4548                                       Tel:   +86-10-6260-5568
Email:   rita.fong@fticonsulting.com                  Email:   zhaosisi@xdf.cn, 

BEIJING, April 23, 2024 /PRNewswire/ -- At 10:00 am on April 22, 2024, Milan time, Tan Xuguang, Chairman of the Board of Directors of Italy's Ferretti Group, chaired the Ferretti Global Shareholders' Meeting in Beijing and addressed shareholders' inquiries. The primary location for the meeting was in Milan, with Tan Xuguang, the board of directors, board members, and shareholders worldwide participating virtually.

During the meeting, the 2023 Financial Report and Consolidated Financial Report as well as the Report on Remuneration Policy and Remuneration Payment were reviewed and approved. Additionally, two new members were appointed to the board of directors. According to its subsequent announcement, Ferretti's operating income in 2023 reached 1.134 billion euros, marking a year-on-year increase of 10%. Net profit amounted to 83.5 million euros, reflecting a substantial year-on-year growth of 38%. The company's orders in hand totaled 1.491 billion euros, showing a notable year-on-year increase of 15%. Notably, the growth rate of net profit outpaced that of revenue, reaching the highest level in the company's history. Ferretti also achieved a significant milestone by successfully returning to the Milan Exchange for listing, thereby becoming the world's first company to be dual-listed in Hong Kong and Italy.

The Ferretti Group is among the oldest and most esteemed Italian luxury yacht manufacturers, renowned as a leader in the global luxury yacht and leisure ship industry. The group boasts ownership of the world's most prestigious yacht brands, each offering unique and complementary advantages within the industry. In 2008, amidst the global financial crisis, Ferretti faced significant challenges and fell into a development dilemma primarily due to poor management. In 2012, Weichai Group, a globally recognized equipment manufacturing group, strategically reorganized Ferretti, initiating a journey of strategic cooperation between the two parties. Weichai Group leveraged its strong synergistic resources to assist Ferretti in swiftly reversing its development decline and setting out on a path of rapid and healthy growth. Tan Xuguang, Chairman of the Board of Directors of Weichai Group and also Chairman of the Board of Directors of Ferretti, was honored with the "Leonardo International Award" by the Italian government. This prestigious accolade recognized his outstanding contributions to the strategic reorganization of Ferretti and the fostering of economic exchanges between China and Italy.

At the meeting, the participating shareholders expressed full affirmation of Ferretti's rapid development and conveyed high expectations for the company to maintain its leading position in the global yacht industry and further expand its edge in the industry in the future. Tan Xuguang emphasized that Weichai Group will continue to steadfastly support the development of Ferretti, working together to elevate Ferretti into an unequivocal standout in the global yacht industry. The aim is to continuously generate greater value for investors and stakeholders alike.

HANNOVER, Germany, April 23, 2024 /PRNewswire/ -- For the first time in five years, Shanghai Electric ("the Company) (SEHK:2727, SSE:601727) is returning to Hannover Messe, the world's leading industrial trade fair, bringing its innovative industrial equipment solutions to European and global industry peers, along with its signature energy equipment solutions. At the five-day event, Shanghai Electric will be exhibiting at Hall 12, Stand D66 of the Hannover Exhibition Center, where the Company will showcase its capabilities in driving industrial energy transformation and automation under the theme "Energize Your Industrial Automation".

From cutting-edge power systems to zero-carbon industrial parks, as well as intelligent manufacturing lines and efficient industrial drives, attendees will be able to witness the Company's latest technological solutions and achievements across multiple dimensions.

Innovation at the Forefront: Shanghai Electric Also to Bring Pioneering Smart Energy Solutions for Global Sustainable Development.

The Company is presenting its industry-proven sustainable energy equipment solutions, including:

• 16MW+ Offshore Wind Turbine: The 16MW+ floating offshore wind turbines, coupled with the Poseidon platform, feature over 40 key adaptability technology improvements compared to fixed offshore wind turbines. These advancements ensure reliable performance in complex environments, with core advantages in reliability, smart maintenance, and modular scalability.
• Integrated Photovoltaics (PV) Solution: The Company is presenting a suite of PV integration solutions suitable for multiple scenarios, including combined PV and solar thermal power generation, solar thermal energy storage, solar-powered desalination, and energy-saving solar thermal heating, along with the necessary equipment and solutions. The notable sandbox of its signature 950 MW PV hybrid power generation in Dubai includes a 100 MW concentrated solar power ("CSP") tower, three 200 MW parabolic trough CSP plants, and 250 MW of PV capacity.
• Diverse Energy Storage Solutions: Catering to international markets with comprehensive displays of various energy storage forms such as flywheel energy storage, lithium batteries, and flow battery technologies, among others. Through its proactive approach in multiple directions, it is capable of offering a one-stop service for various superior storage options and integrated equipment and services for reactive power compensation. Utilizing the integrated benefits of various equipment types, it aims to tackle the instability of wind and solar power, offering a variety of energy storage technological equipment and solutions for grid dispatch and stability enhancement.
• Hydrogen Energy Integration: Demonstrating the leading PEM electrolysis H₂ production products alongside the Alkaline Water electrolysis equipment, as well as an integrated "produce-store-transfer-use" system solution.
• Comprehensive Transmission and Distribution Lifecycle Power Solutions: The exhibition showcased the main areas covered by the current 1000kV and below power transmission and distribution equipment, including transformers, wires and cables, switch components, power electronics, complete sets of switchgear, and box-type substations. It formed an entire industry chain system featuring intelligent, environmentally friendly, digital primary and secondary equipment, integrated design and engineering, and professional services.
• Zero-Carbon Industrial Park Construction: Addressing fragmentation issues in zero-carbon park construction through extensive exploration and leading global partners to achieve low-carbon transitions from the planning and design stages, through construction, to operation.

Pushing Boundaries in Intelligent Manufacturing

Shanghai Electric is showcasing advancements that extend the boundaries of intelligent manufacturing:

• Lithium Battery Production Automation Line: Shanghai Electric demonstrates its all-encompassing solutions provided to global users, including planning and design for battery automation production, process realization, power assistance, and environmental control. These solutions extend across the entire production cycle of batteries, from producing electrode battery slurry to coating, calendering and slicing, folding, rolling, assembling, formation and separation, modules, Packaging Assembly Configuration Kit (PACK), and logistics, fully catering to the automation, digitalization, and intelligence production requirements of customers.
• Aerospace Automated Assembly Solutions: Broetje Automation, under the company's umbrella, featured its collaborative robots at the show. Specializing in automated assembly services for the aerospace sector, Broetje Automation focuses on riveting and assembling processes for large aircraft parts made of metal or carbon fiber. Its offerings encompass automatic drilling and riveting systems, equipment for processing composite materials, services to optimize process flows, and the integration of production lines, along with crucial enabling services.
• Basic Industrial Components: The Company demonstrates high-performance ceramic bearings for electric vehicle motors with the P1 drive system, which excel in high-speed environments, withstand high temperatures, and are resistant to both magnetic and electrical erosion. The HALO system, crafted from high-strength grade 5 titanium alloy for a lightweight design, is implemented in Formula 1 racing to ensure driver safety by offering unparalleled load-bearing strength.
• 80MW-Class Motors for LNG Solution: An all-electric LNG solution featuring an ultra-high-speed variable-frequency explosion-proof synchronous motor and a speed-regulating inverter. The product is designed with efficiency, stability, and reliability in mind, making it suitable for widespread use in industries such as oil and gas, petrochemicals, new energy, and metallurgy.

For more information about the exhibited solutions, please visit us at Booth Hall 12, Stand D66 at the Hannover Exhibition Center, or explore the company website at https://www.shanghai-electric.com/